Impact of Omega 3 Fatty Acid Supplementation on Aromatase in Obese Subjects

Completed · Early Phase 1

Conditions studied: Breast Cancer

In brief

Assess the impact of dietary omega 3 free fatty acids and/or letrozole on obese, postmenopausal breast cancer patients.

Key facts

Study ID

NCT02538484

Run by

The University of Texas Health Science Center at San Antonio

People needed

24

Starts

2016-04-01

Expected to finish

2020-03-26

Last updated by the study team

2023-07-17

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• At least 18 years of age.
• Postmenopausal as confirmed in medical history
• Ability to understand the purposes and risks of the study and has signed a written informed consent form approved by the investigator's IRB (Institutional Review Board)/Ethics Committee.
• Estrogen receptor positive breast cancer. Body mass index of 30 or greater.
• Consented for tissue collection on CTRC (Cancer Therapy and Research Center) repository 07-32

You may not qualify if…

• Cachexia
• Active systemic illness (infection including viral illnesses such as Hepatitis and HIV)
• Chronic use of NSAIDs (nonsteroidal anti-inflammatory drugs) aspirin or omega-3 free fatty acid supplementation within the last 60 days (defined as greater than or equal to 7 consecutive days)
• Any NSAIDs aspirin or omega-3 free fatty acid supplementation within the last 14 days
• History of medical noncompliance
• Scheduled date of surgical resection that would limit the amount of time taking the intervention to less than 21 days

Where it is running

• Houston Methodist Cancer Center at Texas Medical Center — Houston, Texas, United States
• Mays Cancer Center, UT Health San Antonio — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.